Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Abstract Cancer vaccines initiate antitumor responses in a subset of patients, but the lack of clinically meaningful biomarkers to predict treatment response limits their development. Here, we design multifunctional RNA-loaded magnetic liposomes to initiate potent antitumor immunity and function as an early biomarker of treatment response. These particles activate dendritic cells (DCs) more effectively than electroporation, leading to superior inhibition of tumor growth in treatment models. Inclusion of iron oxide enhances DC transfection and enables tracking of DC migration with magnetic resonance imaging (MRI). We show that T2*-weighted MRI intensity in lymph nodes is a strong correlation of DC trafficking and is an early predictor of antitumor response. In preclinical tumor models, MRI-predicted “responders” identified 2 days after vaccination had significantly smaller tumors 2–5 weeks after treatment and lived 73% longer than MRI-predicted “nonresponders”. These studies therefore provide a simple, scalable nanoparticle formulation to generate robust antitumor immune responses and predict individual treatment outcome with MRI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
Shen, Z., Reznikoff, G., Dranoff, G., & Rock, K. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2723 · Cited by 846
de Vries, I. J. M., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J. G., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1154 · Cited by 821
A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy
Cho, N.-H., Cheong, T.-C., Min, J. H., Wu, J. H., Lee, S. J., Kim, D., Yang, J.-S., Kim, S., Kim, Y. K., & Seong, S.-Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.149 · Cited by 514
In vivo MRI cell tracking: clinical studies
Bulte, J. W. M. (2009) · American Journal of Roentgenology · doi:10.2214/ajr.09.3107 · Cited by 430
Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles
Sayour, E. J., De Leon, G., Pham, C., Grippin, A., Kemeny, H., Chua, J., Huang, J., Sampson, J. H., Sanchez-Perez, L., Flores, C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1256527 · Cited by 93
Self-citation
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Recent progress of magnetic nanoparticles in biomedical applications: A review
Anik, M. I., Hossain, M. K., Hossain, I., Mahfuz, A. M. U. B., Rahman, M. T., & Ahmed, I. (2021) · Nano Select · doi:10.1002/nano.202000162 · Cited by 300
Ruan, Y., Xiong, Y., Fang, W., Yu, Q., Mai, Y., Cao, Z., Wang, K., Lei, M., Xu, J., Liu, Y., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01524-4 · Cited by 85
“In AD diagnostics, current visualization of β-amyloid is based on positron emission tomography (PET) radiotracer technology [5].”
MethodMultifunctional Magnetic Nanoparticles for Dynamic Imaging and Therapy
Ko, M. J., Hong, H., Choi, H., Kang, H., & Kim, D. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200053 · Cited by 29
Potential mechanisms and clinical applications of static magnetic field therapy in glioma
Sun, Z., Zhu, K., Zhao, W., Fei, X.-F., Shi, L., & Zhang, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1594874 · Cited by 2
Metadata
- Authors
- Grippin, A. J., Wummer, B., Wildes, T., Dyson, K., Trivedi, V., Yang, C., Sebastian, M., Mendez-Gomez, H. R., Padala, S., Grubb, M., Fillingim, M., Monsalve, A., Sayour, E. J., Dobson, J., & Mitchell, D. A.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-11-15
- Volume
- 13
- Issue
- 12
- Pages
- 13884-13898
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2988051443
- Cited by
- 93
- References
- 12
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.